Table 3.
Clinical characteristics and [18F]FDG PET/CT findings in patients with interstitial pneumonia
Control period N = 14 | COVID-19 period N = 24 | Overall N = 38 | p value | |
---|---|---|---|---|
Age | 0.916 | |||
Mean (SD) | 67.9 (12.2) | 68.5 (11.9) | 68.3 (11.9) | |
Median (Q1–Q3) | 68.9 (60.8–78.3) | 71.7 (60.1–76.7) | 70.7 (60.8–77.5) | |
Min-max | 41.2–84.8 | 44.9–88.7 | 41.2–88.7 | |
Sex | 0.101 | |||
Female | 10 (71.4) | 10 (41.7) | 20 (52.6) | |
Male | 4 (28.6) | 14 (58.3) | 18 (47.4) | |
Tumor site | 0.388 | |||
Lung | 3 (21.4) | 6 (25.0) | 9 (23.7) | |
Gastrointestinal system | 2 (14.3) | 5 (20.8) | 7 (18.4) | |
Breast | 4 (28.6) | 4 (16.7) | 8 (21.1) | |
Gynecological apparatus | 0 (0.0) | 1 (4.2) | 1 (2.6) | |
Multiple neoplasm | 2 (14.3) | 3 (12.5) | 5 (13.2) | |
Head/neck | 0 (0.0) | 3 (12.5) | 3 (7.9) | |
Hematological system | 1 (7.1) | 0 (0.0) | 1 (2.6) | |
Melanoma and soft tissue | 0 (0.0) | 2 (8.3) | 2 (5.3) | |
Unknown | 2 (14.3) | 0 (0.0) | 2 (5.3) | |
PET/CT indication | 0.170 | |||
Staging/Restaging | 10 (71.4) | 15 (62.5) | 25 (65.8) | |
Treatment response | 4 (28.6) | 4 (16.7) | 8 (21.1) | |
Follow-up | 0 (0.0) | 5 (20.8) | 5 (13.2) | |
[18F]FDG PET/CT findings | ||||
SUVmax | 0.562 | |||
Mean (SD) | 3.1 (1.1) | 3.6 (1.9) | 3.4 (1.7) | |
Median (Q1–Q3) | 2.9 (2.2–3.4) | 3.0 (2.5–4.3) | 3.0 (2.3–4.0) | |
Min-max | 2.1–5.3 | 1.9–11.3 | 1.9–11.3 | |
Laterality | 0.081 | |||
Monolateral abnormalities | 8 (57.1) | 6 (25.0) | 14 (36.8) | |
Bilateral abnormalities | 6 (42.9) | 18 (75.0) | 24 (63.2) | |
Alterations | 0.684 | |||
Ground-glass opacities | 12 (85.7) | 18 (75.0) | 30 (78.9) | |
Ground-glass opacities and consolidations | 2 (14.3) | 6 (25.0) | 8 (21.1) | |
Enlarged lymph nodes | 6 (42.9) | 15 (65.2) | 21 (56.8) | 0.305 |
Missing | 0 | 1 | 1 | |
SUVmax at lymph nodes | 0.668 | |||
Mean (SD) | 4.5 (2.5) | 3.9 (2.2) | 4.1 (2.3) | |
Median (Q1–Q3) | 3.5 (3.2–4.1) | 3.7 (2.8–4.5) | 3.5 (3.0–4.1) | |
Min-max | 3.1–9.6 | 1.9–11.2 | 1.9–11.2 |
SD standard deviation; SUVmax maximum standardiazed uptake value